XP Chemistries
0.18 SEK
-1.35 %
Less than 1K followers
XPC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for XP Chemistries
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | 0.3 | 1.1 | 0.7 | 0.3 | 0.3 |
| growth-% | 279.9 % | -37.7 % | -57.6 % | 16.9 % | |
| EBITDA | -5.0 | -8.5 | -9.5 | -7.9 | -9.0 |
| EBIT | -5.2 | -9.9 | -10.1 | -9.3 | -10.6 |
| Profit before taxes | -5.7 | -9.8 | -10.0 | -8.8 | -10.6 |
| Net income | -4.5 | -7.9 | -8.0 | -7.1 | -8.5 |
| EPS | -0.15 | -0.25 | -0.25 | -0.05 | -0.03 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| EBITDA-% | -1,775.6 % | -801.9 % | -1,433.3 % | -2,814.3 % | -2,762.8 % |
| EBIT-% | -1,877.4 % | -930.2 % | -1,531.8 % | -3,317.9 % | -3,224.3 % |
| ROE | -14.5 % | -27.2 % | -31.3 % | -33.1 % | -23.1 % |
| ROI | -13.2 % | -25.8 % | -29.6 % | -31.4 % | -22.4 % |